Table 3. Average number and frequency of single-nucleotide variants (SNVs) detected on H3N2 sequences of bronchoalveolar lavage fluid (BALF) samples by coding regions and treatment groups.
| Segment | PRIME BOOST (n = 12)* | SINGLE LAIV (n = 9) | NO VAC (n = 7) | ||||||
|---|---|---|---|---|---|---|---|---|---|
| No. of sequences† | Mean no. of SNV (SD) | Mean SNV frequency (SD) | No. of sequences | Mean no. of SNV (SD) | Mean SNV frequency (SD) | No. of sequences | Mean no. of SNV (SD) | Mean SNV frequency (SD) | |
| PB2 | 10 | 4.9 (3.8) | 0.155 (0.287) | 6 | 4.0 (2.9) | 0.130 (0.259) | 4 | 3.3 (0.5) | 0.147 (0.162) |
| PB1 | 9 | 3.1 (2.7) | 0.119 (0.231) | 6 | 3.2 (3.8) | 0.044 (0.038) | 3 | 2.3 (1.2) | 0.024 (0.019) |
| PB1-F2 | 9 | 0.1 (0.3) | 0.024 (NA) | 6 | 0.0 (0.0) | 0.000 (0.000) | 3 | 0.0 (0.0) | 0.000 (0.000) |
| PA | 8 | 2.5 (2.7) | 0.060 (0.096) | 6 | 2.2 (1.8) | 0.054 (0.106) | 4 | 2.0 (0.8) | 0.033 (0.028) |
| PA-X | 8 | 0.8 (0.9) | 0.063 (0.069) | 6 | 0.7 (1.2) | 0.015 (0.003) | 4 | 0.5 (0.6) | 0.038 (0.011) |
| HA | 10 | 1.2 (1.2) | 0.036 (0.060) | 6 | 1.7 (0.8) | 0.092 (0.179) | 4 | 1.0 (0.0) | 0.024 (0.015) |
| NP | 11 | 3.0 (3.1) | 0.102 (0.246) | 6 | 1.7 (1.2) | 0.080 (0.169) | 4 | 1.0 (0.8) | 0.023 (0.008) |
| NA | 11 | 2.3 (1.9) | 0.019 (0.012) | 6 | 1.8 (1.7) | 0.035 (0.023) | 4 | 1.8 (1.5) | 0.170 (0.256) |
| M1 | 11 | 1.3 (1.7) | 0.041 (0.079) | 6 | 0.7 (1.2) | 0.017 (0.011) | 4 | 0.0 (0.0) | 0.000 (0.000) |
| M2 | 11 | 0.5 (0.8) | 0.032 (0.024) | 6 | 0.3 (0.5) | 0.018 (0.004) | 4 | 0.0 (0.0) | 0.000 (0.000) |
| NS1 | 10 | 1.3 (1.4) | 0.078 (0.110) | 6 | 0.3 (0.5) | 0.033 (0.016) | 4 | 1.0 (0.8) | 0.014 (0.003) |
| NS2 | 10 | 0.5 (0.5) | 0.122 (0.167) | 6 | 0.3 (0.8) | 0.052 (0.059) | 4 | 0.8 (1.0) | 0.036 (0.032) |
SD, standard deviation; NA, not applicable; LAIV: live-attenuated influenza virus; IAV, influenza A virus.
*
‘n’ represents the number of BALF samples successfully sequenced by Illumina by treatment groups.
†
The ‘No. of sequences’ columns represent the number of sequences from H3N2 IAVs for any given protein from the total available samples (n) within each treatment group.